ISSN: 1859 - 2872
Preliminary results of induction chemotherapy regimen gemcitabin-cisplatin followed by concurrent chemoradiotherapy in stage III-IVA nasopharyngeal carcinoma
Main Article Content
Keywords
Abstract
Objective: To evaluate the preliminary results of induction chemotherapy regimen gemcitabin-cisplatin followed by concurrent chemoradiotherapy in stage III-IVA nasopharyngeal carcinoma patients. Subject and method: The uncontrolled clinical intervention was conducted on 41 stage III-IVA nasopharyngeal carcinoma patients (with N3 accounting for 46.3%) who underwent induction chemotherapy with 3 cycles of gemcitabin 1000mg/m2 on day 1 and 8 plus cisplatin 80mg/m2 on day 1, followed by concurrent radiotherapy with weekly cisplatin 40mg/m2 from March 2020 to February 2023 at the 108 Military Central Hospital. Result: At 1 month after radiotherapy, the complete and partial response rates were 92.7% and 7.3%, respectively. The median follow-up time was 16 months (range: 6-33 months). The rates of locoregional relapse-free survival, disease-free survival, distant metastasis-free survival, and overall survival at 2 years were 85.2%, 66.9%, 82.9%, and 92.3%, respectively. Grade 3-4 hematologic toxicity occurred commonly (51.3%), mainly manifested as neutropenia. Conclusion: The induction chemotherapy with gemcitabine-cisplatin followed by concurrent radiotherapy for the treatment of advanced-stage nasopharyngeal carcinoma initially achieved relatively high rates of locoregional control and distant metastasis-free survival. However, this regimen was associated with a high incidence of hematologic toxicity.
Article Details
References
2. Chen Q, Shen L and Li S (2023) Tumor volume reduction after induction chemotherapy with gemcitabine plus cisplatin in nasopharyngeal carcinoma. Eur Arch Otorhinolaryngol 280(5): 2497-509.
3. Chen YP, Ismaila N, Chua MLK et al (2021) Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. J Clin Oncol 39(7): 840-859.
4. Li WF, Chen NY, Zhang N et al (2019) Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial. Int J Cancer 145(1): 295-305.
5. Pan JJ, Ng WT, Zong JF et al (2016) Proposal for the 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. Cancer 122(4): 546-558.
6. Yang Q, Cao SM, Guo L et al (2019) Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase III multicentre randomised controlled trial. Eur J Cancer 119: 87-96.
7. Zhang Y, Chen L Hu GQ et al (2019) Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. N Engl J Med 381(12): 1124-1135.
8. Zheng L, Liao W, Xu P et al (2018) Tumor volume reduction after gemcitabine plus cisplatin induction chemotherapy in locally advanced nasopharyngeal cancer: Comparison with paclitaxel and cisplatin regimens. Med Sci Monit 24: 8001-8008.
9. Zhu J, Duan B, Shi H et al (2019) Comparison of GP and TPF induction chemotherapy for locally advanced nasopharyngeal carcinoma. Oral Oncol 97: 37-43.
10. International Agency for Research on Cancer - World Health Organization. GLOBOCAN 2020: Nasopharynx, accessed May 28-2021, from https://gco.iarc.fr/today/data/factsheets/cancers/4-Nasopharynx-fact-sheet.pdf.
Article Sidebar
